AS03- and MF59-Adjuvanted Influenza Vaccines in Children

Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season

(2017) Richard Pebody et al.   Eurosurveillance

Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010–2014

(2017) Brendan Flannery et al.   PEDIATRICS

Systems analysis of protective immune responses to RTS,S malaria vaccination in humans

(2017) Dmitri Kazmin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake

(2017) Frank Liang et al.   Science Translational Medicine

Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis

(2017) Louise E. Lansbury et al.   VACCINE

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans

(2017) Wivine Burny et al.   Frontiers in Immunology

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial

(2017) Robert A. van den Berg et al.   Frontiers in Immunology

Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy

(2017) Eurosurveillance editorial team   Eurosurveillance

Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial

(2017) Leigh M. Howard et al.   PLoS One

Where are we in our understanding of the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines?

(2016) K. Johansen et al.   BIOLOGICALS

Competition within the virus-specific CD4 T-cell pool limits the T follicular helper response after influenza infection

(2016) Matthew R Olson et al.   IMMUNOLOGY AND CELL BIOLOGY

Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events

(2016) Olga Sobolev et al.   NATURE IMMUNOLOGY

Recommendations for Prevention and Control of Influenza in Children, 2016-2017

(2016)   PEDIATRICS

Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood

(2016) Helder I. Nakaya et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children

(2016) Jorgen Stassijns et al.   VACCINE

A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve

(2016) Ying Fu et al.   Nature Communications

From discovery to licensure, the Adjuvant System story

(2016) Nathalie Garçon et al.   Human Vaccines & Immunotherapeutics

Defective T Memory Cell Differentiation after Varicella Zoster Vaccination in Older Individuals

(2016) Qian Qi et al.   PLoS Pathogens

Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans

(2016) Fabiana Spensieri et al.   PLoS One

ICOS+PD-1+CXCR3+ T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination

(2016) Salah-Eddine Bentebibel et al.   Scientific Reports

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

(2015) Beatris Mastelic Gavillet et al.   JOURNAL OF IMMUNOLOGY

High Preexisting Serological Antibody Levels Correlate with Diversification of the Influenza Vaccine Response

(2015) Sarah F. Andrews et al.   JOURNAL OF VIROLOGY

Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age

(2015) Luisanna Zedda et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination

(2015) Simon Thebault et al.   PLoS One

Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age

(2015) Markus Knuf et al.   VACCINE

Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults

(2015) Steven Black   VACCINE

Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children

(2015) Åke Örtqvist et al.   VACCINE

Molecular signatures of vaccine adjuvants

(2015) Thorunn Olafsdottir et al.   VACCINE

Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains

(2015) Sarah Lartey et al.   Human Vaccines & Immunotherapeutics

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

(2015) José Garcia-Sicilia et al.   Human Vaccines & Immunotherapeutics

Influenza vaccination in children primed with MF59®-adjuvanted or non-adjuvanted seasonal influenza vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

(2015) Markus Knuf et al.   Human Vaccines & Immunotherapeutics

Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?

(2015) Salaheddin M. Mahmud et al.   PLoS One

Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses

(2014) John S. Tsang et al.   CELL

Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England

(2014) Anne Marie Winstone et al.   DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY

Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010

(2014) D O’Flanagan et al.   Eurosurveillance

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants

(2014) S. Sohail Ahmed et al.   JOURNAL OF AUTOIMMUNITY

The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells

(2014) A. Seubert et al.   JOURNAL OF IMMUNOLOGY

Virus-Specific Antibody Secreting Cell, Memory B-cell, and Sero-Antibody Responses in the Human Influenza Challenge Model

(2014) Kuan-Ying Arthur Huang et al.   JOURNAL OF INFECTIOUS DISEASES

Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine Correlate With the Kinetics and Magnitude of Interferon Signaling in Children

(2014) Raquel G. Cao et al.   JOURNAL OF INFECTIOUS DISEASES

Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial

(2014) Terry Nolan et al.   JOURNAL OF INFECTIOUS DISEASES

Crucial Roles of Interleukin-7 in the Development of T Follicular Helper Cells and in the Induction of Humoral Immunity

(2014) Y. B. Seo et al.   JOURNAL OF VIROLOGY

Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age

(2014) Markus Knuf et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Heterologous Prime-Boost Vaccination with MF59-Adjuvanted H5 Vaccines Promotes Antibody Affinity Maturation towards the Hemagglutinin HA1 Domain and Broad H5N1 Cross-Clade Neutralization

(2014) Surender Khurana et al.   PLoS One

Risk of Narcolepsy Associated with Inactivated Adjuvanted (AS03) A/H1N1 (2009) Pandemic Influenza Vaccine in Quebec

(2014) Jacques Montplaisir et al.   PLoS One

Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

(2014) Outi Vaarala et al.   PLoS One

Seeking Help: B Cells Adapting to Flu Variability

(2014) R. G. van der Most et al.   Science Translational Medicine

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans

(2014) Edgar Turner Overton et al.   VACCINE

The adjuvant component α-tocopherol triggers via modulation of Nrf2 the expression and turnover of hypocretin in vitro and its implication to the development of narcolepsy

(2014) Sanita Masoudi et al.   VACCINE

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children

(2014) Terry Nolan et al.   VACCINE

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

(2014) Adib Rodriguez Solares et al.   Journal of Infection in Developing Countries

Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France

(2013) Yves Dauvilliers et al.   BRAIN

B Cell Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H1N1 Influenza Virus Vaccination

(2013) Mark Y. Sangster et al.   Clinical and Vaccine Immunology

Administration of AS03B-adjuvanted A(H1N1)pdm09 Vaccine in Children Aged

(2013) K. Hoschler et al.   CLINICAL INFECTIOUS DISEASES

Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine

(2013) Joon Young Song et al.   JOURNAL OF MEDICAL VIROLOGY

Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action

(2013) Charlotte I S Barker et al.   LANCET INFECTIOUS DISEASES

Apoptosis and other immune biomarkers predict influenza vaccine responsiveness

(2013) D. Furman et al.   Molecular Systems Biology

Molecular signatures of antibody responses derived from a systems biology study of five human vaccines

(2013) Shuzhao Li et al.   NATURE IMMUNOLOGY

Influenza-Associated Pediatric Deaths in the United States, 2004-2012

(2013) K. K. Wong et al.   PEDIATRICS

Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands

(2013) Leonoor Wijnans et al.   PLoS One

CD4+ T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy

(2013) A. K. De la Herran-Arita et al.   Science Translational Medicine

Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination

(2013) S.-E. Bentebibel et al.   Science Translational Medicine

Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A

(2013) M.S. Heier et al.   SLEEP MEDICINE

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

(2013) Samuele Calabro et al.   VACCINE

An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10–17 years of age

(2013) Airi Poder et al.   VACCINE

Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals

(2013) Yong-Hong Zhang et al.   Nature Communications

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

(2013) E. Miller et al.   BMJ-British Medical Journal

Cross-protection against drifted influenza viruses

(2013) Andrea Orsi et al.   Human Vaccines & Immunotherapeutics

Integrative genomic analysis of the human immune response to influenza vaccination

(2013) Luis M Franco et al.   eLife

Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects

(2012) Iván Bihari et al.   Clinical and Vaccine Immunology

Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus

(2012) Francesca Buricchi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The history of MF59®adjuvant: a phoenix that arose from the ashes

(2012) Derek T O’Hagan et al.   Expert Review of Vaccines

Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial

(2012) Yan-Ping Li et al.   Influenza and Other Respiratory Viruses

B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1

(2012) Alex Karnowski et al.   JOURNAL OF EXPERIMENTAL MEDICINE

MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action

(2012) E. Caproni et al.   JOURNAL OF IMMUNOLOGY

Myocardial Injury and Bacterial Pneumonia Contribute to the Pathogenesis of Fatal Influenza B Virus Infection

(2012) Christopher D. Paddock et al.   JOURNAL OF INFECTIOUS DISEASES

Pandemic influenza A (H1N1) 2009 vaccination in children: A UK perspective

(2012) Philip CS de Whalley et al.   JOURNAL OF PAEDIATRICS AND CHILD HEALTH

IFITM3 restricts the morbidity and mortality associated with influenza

(2012) Aaron R. Everitt et al.   NATURE

Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children

(2012) Stan L. Block et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Randomized, Multicenter Trial of a Single Dose of AS03-adjuvanted or Unadjuvanted H1N1 2009 Pandemic Influenza Vaccine in Children 6 Months to

(2012) Joanne M. Langley et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland

(2012) Markku Partinen et al.   PLoS One

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

(2012) G.-M. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection

(2012) T. Onodera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza

(2012) Åke Örtqvist et al.   VACCINE

A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic

(2012) Humberto Reynales et al.   VACCINE

Influenza viruses and cross-reactivity in healthy adults: Humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus

(2012) Anna M. Iorio et al.   VACCINE

Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: Systematic review and meta-analyses

(2012) Jiehui Kevin Yin et al.   VACCINE

Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine

(2012) Akihiko Saitoh et al.   Human Vaccines & Immunotherapeutics

Homologous and heterologous antibody responses to a one-year booster dose of an MF59®: Adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

AID Activity in B Cells Strongly Correlates with Polyclonal Antibody Affinity Maturation in-vivo Following Pandemic 2009-H1N1 Vaccination in Humans

(2012) Surender Khurana et al.   PLoS Pathogens

Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial

(2011) Alessandra Viganò et al.   Clinical and Vaccine Immunology

Effectiveness of an Adjuvanted Monovalent Vaccine Against the 2009 Pandemic Strain of Influenza A(H1N1)v in Stockholm County, Sweden

(2011) A. Ortqvist et al.   CLINICAL INFECTIOUS DISEASES

MF59™-adjuvanted seasonal influenza vaccine in young children

(2011) Joan Puig-Barberà et al.   Expert Review of Vaccines

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age

(2011) Adriano Arguedas et al.   Human vaccines & immunotherapeutics

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

(2011) Angelika Banzhoff et al.   Human vaccines & immunotherapeutics

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

(2011) Harish Nair et al.   LANCET

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

(2011) Michael T Osterholm et al.   LANCET INFECTIOUS DISEASES

Programming the magnitude and persistence of antibody responses with innate immunity

(2011) Sudhir Pai Kasturi et al.   NATURE

Systems biology of vaccination for seasonal influenza in humans

(2011) Helder I Nakaya et al.   NATURE IMMUNOLOGY

Stalking Influenza Diversity with a Universal Antibody

(2011) Charles J. Russell   NEW ENGLAND JOURNAL OF MEDICINE

Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children

(2011) Timo Vesikari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

(2011) Steven Black et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effectiveness of Pandemic H1N1 Vaccine Against Influenza-Related Hospitalization in Children

(2011) R. Gilca et al.   PEDIATRICS

Influenza A/H1N1 MF59-Adjuvanted Vaccine in Preterm and Term Children Aged 6 to 23 Months

(2011) S. Esposito et al.   PEDIATRICS

Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10

(2011) Helmut Uphoff et al.   PLoS One

H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination

(2011) M. Anthony Moody et al.   PLoS One

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

(2011) Theodore F. Tsai et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine

Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: Population-based case–control study

(2011) Salaheddin Mahmud et al.   VACCINE

Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children

(2011) Wanatpreeya Phongsamart et al.   VACCINE

Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009–2010: Cohort and case-control study

(2011) Jesús Castilla et al.   VACCINE

Safety of MF-59 adjuvanted vaccine for pandemic influenza: Results of the vaccination campaign in an Italian health district

(2011) Cristina Cristiani et al.   VACCINE

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

(2011) Sandra Morel et al.   VACCINE

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

(2011) Sara Meier et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents

(2011) J. Garcia-Sicilia et al.   VACCINE

Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study

(2011) Giovanni Della Cioppa et al.   VACCINE

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

(2010) Yuji Yasuda et al.   ADVANCES IN THERAPY

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

(2010) E. Fragapane et al.   Clinical and Vaccine Immunology

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

(2010) Paolo Durando et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children

(2010) P. G. Van Buynder et al.   Influenza and Other Respiratory Viruses

Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities

(2010) Mark Loeb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in England

(2010) N. Andrews et al.   JOURNAL OF INFECTIOUS DISEASES

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients

(2010) S. Esposito et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years

(2010) Javier Díez-Domingo et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence

(2010) T. Vesikari et al.   PEDIATRICS

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates

(2010) Filippo Ansaldi et al.   VACCINE

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months

(2010) Alfonso Carmona et al.   VACCINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults

(2009) Daniel Wai-Sing Chu et al.   VACCINE

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

(2009) T. Vesikari et al.   VACCINE

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages

(2009) B. Camilloni et al.   VACCINE

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

(2008) Denis Gaucher et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Dual role for B-1a cells in immunity to influenza virus infection

(2008) Youn Soo Choi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

(2008) Troy D Querec et al.   NATURE IMMUNOLOGY

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

(2008) Hans C. Rümke et al.   VACCINE

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE

Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

(2008) Filippo Ansaldi et al.   VACCINE